Product Name

:

URI-TAC

Chemical Name

:

Flavoxate HCl

Therapeutic Category

:

Urinary tract drugs

Pharmacologic Category

:

Antispasmodic Agent, Urinary

Pharmaceutical Form

:

Tablets

Composition

:

Flavoxate HCl 200mg

Dosing

Dosing: Adult
Urinary spasms: Oral: 100-200 mg 3-4 times/day; reduce the dose when symptoms improve.

Dosing: Pediatric
Children >12 years: Refer to adult dosing.

Dosing: Geriatric
Refer to adult dosing.

Use

Antispasmodic to provide symptomatic relief of dysuria, nocturia, suprapubic pain, urgency, and incontinence due to detrusor instability and hyper-reflexia in elderly with cystitis, urethritis, urethrocystitis, urethrotrigonitis, and prostatitis

Adverse Reactions

Frequency not defined.
Cardiovascular: Palpitations, tachycardia
Central nervous system: Confusion (especially in the elderly), drowsiness, fatigue, headache, hyperpyrexia, nervousness, vertigo
Dermatologic: Rash, urticaria
Gastrointestinal: Constipation, dry throat, nausea, vomiting, xerostomia
Genitourinary: Dysuria
Hematologic: Leukopenia
Ocular: Blurred vision, intraocular pressure increased

Contraindications

Hypersensitivity to flavoxate; pyloric or duodenal obstruction; GI hemorrhage; GI obstruction; ileus; achalasia; obstructive uropathies of lower urinary tract (BPH)

Warnings / Precautions Drug

Concerns related to adverse effects:
• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).
• Ocular disturbances: May cause ocular disturbances; patients must be advised of potential effects.
• Vertigo: May cause vertigo; patients must be advised of potential effects.
Disease-related concerns:
• Glaucoma: Use with caution in patients with suspected glaucoma.

Interactions

AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. Risk C: Monitor therapy
Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial. Risk C: Monitor therapy
Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics. Exceptions: Levocabastine (Nasal); Paliperidone. Risk C: Monitor therapy
Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids. Risk C: Monitor therapy
OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. Risk C: Monitor therapy
Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Risk D: Consider therapy modification
Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract. Risk D: Consider therapy modification
RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. Risk C: Monitor therapy
Secretin: Anticholinergic Agents may diminish the stimulatory effect of Secretin. Risk D: Consider therapy modification
Ethanol/Nutrition/Herb Interactions
Ethanol: Avoid ethanol (may increase CNS depression).

Pregnancy

B

Lactation

Excretion in breast milk unknown

Mechanism of Action

Synthetic antispasmotic with similar actions to that of propantheline; it exerts a direct relaxant effect on smooth muscles via phosphodiesterase inhibition, providing relief to a variety of smooth muscle spasms; it is especially useful for the treatment of bladder spasticity, whereby it produces an increase in urinary capacity

Pharmacodynamics / Kinetics

Onset of action: 55-60 minutes
Metabolism: To methyl; flavone carboxylic acid active
Excretion: Urine (10% to 30%) within 6 hours